ÂÜÀòÂÒÂ×

With degrees in engineering and finance and an early career in the chemicals industry, Liz soon discovered her passion for bringing innovative medicines to market to prevent or treat life-threatening diseases. Applying a strong analytic framework, strategic discipline, and commercial experience in leading high-growth businesses, she brings a deep commitment to partnerships with R&D and operating colleagues to benefit patients.

Liz previously served as the worldwide vice president and commercial leader in the infectious diseases and vaccines global commercial strategy organization at Janssen Pharmaceuticals, a Johnson & Johnson company. In this role, she led strategy, global commercialization, and market access for respiratory infections, HIV, sexually transmitted infections, and bacterial pathogens portfolios. Liz also helped develop and execute Janssen¡¯s first global vaccines strategy and played a key role in the acquisition of vaccines company Crucell N.V. She held several leadership positions within Johnson & Johnson, including worldwide vice president, immunology & respiratory, global strategic marketing, and worldwide vice president, global strategic marketing for the biotechnology, immunology, and oncology business unit. Liz played key roles in the launch or life cycle management of important Janssen brands, including STELARA, SIMPONI, VELCADE, and REMICADE, in the development of numerous early- and medium-stage compounds and in the advancement of therapeutic area and company strategies. During her tenure, she served on the Centocor, Inc. and Crucell management boards, the Centyrex and Betalogics internal venture boards, the BIO R&D management board, and the Pharmaceuticals Group development committee.